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Minimally invasive implantation of a cardioverter-defibrillator
in a small patient
Christopher S. Snyder, MD,a Victor Lucas, MD,a Thomas Young, MD,a Rani Darling, RN,a Geeta Dalal, MDa, and
James E. Davis, MD,b New Orleans, La
The patient is a 3-year-old girl weighing 13 kg, with adiagnosis of long QT syndrome, who experienced an epi-sode of syncope and was found to be in ventricular fibril-lation. She was cardioverted and transported to our insti-
tution. On arrival, she was taken to the operating room for
implantation of an epicardial cardioverter-defibrillator. Because of her
small size, this implantation was performed by using a previously
unreported minimally invasive technique.
Clinical Summary
In the operating room general anesthesia was achieved. A midline
incision was made over the xiphoid that extended 3 cm inferiorly.
The linea alba was divided, and the retrosternal space was entered
and developed. A 3-cm longitudinal pericardial incision was made,
and a retractor was placed inside the pericardial sac to elevate the
sternum.
A 58-cm dual-coil shocking lead (Medtronic 6949) was looped
around the ventricles, with the distal coil coming to rest on the
anterior right ventricular wall and the more proximal portion of the
lead emerging from the posterior pericardial sac along the dia-
phragm. The distal coil was secured with an epicardial-encircling
suture. The midportion of the lead was fixed to the diaphragmatic
surface of the right ventricle. The lead was then looped along the
right ventricular diaphragmatic surface, positioning the proximal
coil from the apex to the base of the heart. Additional epicardial
sutures were used to secure the coil along the inferior ventricular
surface. This maneuver allowed sufficient myocardial mass to be
interposed between the coils.
A 35-cm bipolar, steroid-eluting pace-sense lead (Medtronic
4968) was sutured to the anterior right ventricular wall. On
testing, the lead had excellent sensing and pacing thresholds.
The implantable cardioverter-defibrillator (ICD) pocket was
made in the left abdominal wall. The leads were tunneled from
the preperitoneal space into the pocket. The pacing portion of
the defibrillation lead was capped, and the coil leads were
inserted into the pulse generator (En-Trust, Medtronic). The
bipolar ventricular pace-sense lead was inserted into the pacing
position (Figure 1).
At this point, the ICD was tested 2 times. Ventricular fibrilla-
tion was induced, and the device detected all beats of the tachy-
cardia and delivering a 15-joule shock, successfully restoring sinus
rhythm both times. After fascia and skin closure, the patient was
extubated in the operating room (Figure 2).
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Figure 1. Residual scar post ICD implant. ICD, Implantable car-
dioverter defibrillator.
Figure 2. X-ray illustrating ICD and lead placement. ICD, Implant-
able cardioverter defibrillator.
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Discussion
In recent years, the number of patients meeting the criteria for
implantation of an ICD has increased dramatically. A number of
creative implantation methods have been reported, but each is
faced with its own set of potential complications.1-3 These com-
plications range from postpericardiotomy syndrome4 to lead or
patch trauma and failure.5
There are a number of advantages to this implantation, the first
of which is that the patient avoids a median sternotomy, and the
second of which is that no subcutaneous array is required, there-
fore eliminating the possibility of array failure.
This case is evidence that a minimally invasive approach to
pediatric ICD implantation can be successful. In a patient deter-
mined to be too small for traditional transvenous implantation or
with a lack of venous access, this method of ICD implantation
should be considered.
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Argatroban anticoagulation for renal replacement therapy in patients
with heparin-induced thrombocytopenia after cardiovascular surgery
Andreas Koster, MD, PhD,a Thomas Hentschel, MD,a Tom Groman, MD,b Hermann Kuppe, MD,a
Roland Hetzer, MD, PhD,b Sebastian Harder, MD, PhD,c and Karl-Georg Fischer, MD, PhD,d
Berlin, Frankfurt/Main, and Freiburg, Germany
Heparin-induced thrombocytopenia (HIT) is a severethrombogenic disease requiring the use of alternativeanticoagulants. Argatroban is a synthetic monovalentdirect thrombin inhibitor indicated for prophylaxis
and treatment of thrombosis in patients with HIT. Renal failure
requiring renal replacement therapy (RRT) is a frequent compli-
cation in patients in whom HIT develops after cardiovascular
surgery. The hepatic metabolism and relative short elimination
half-life of 45 minutes render argatroban an interesting option for
anticoagulation during RRT. However, there are scant data on
dosing, pharmacokinetics, safety, and efficacy of argatroban in this
indication. We report our initial experience with argatroban anti-
coagulation for continuous veno-venous hemofiltration (CVVH)
and intermittent hemodialysis (IHD) in 10 patients diagnosed with
HIT after cardiovascular surgery in whom acute renal failure
developed necessitating RRT.
Patients and Methods
After approval by the local ethics committee and having obtained
informed consent, we analyzed the data of 10 patients. In accor-
dance with the study protocol, data were collected for a maximum
of 30 days during RRT. Clinical follow-up of patient outcome was
performed for 3 months after initiation of RRT with argatroban.
All patients had thrombocytopenia after surgery or presented per-
sistent thrombocytopenia postoperatively. In all patients the diag-
nosis of HIT was confirmed in an antibody assay (Particle Gel
Immune Assay; DiaMed, Cressier sur Morat, Switzerland) and in
the heparin-induced platelet aggregation assay. The decision to
perform CVVH (Ultraflux AV 600S; polysulfone high flux hemo-
dialyzer, Fresenius Medical Care AG, Bad Homburg, Germany) or
IHD (Polyflux 140 H; polyamix high flux hemodialyzer, Gambro,
Hechingen, Germany) was based on stability of hemodynamics
and mobility of the patient. In general, RRT was started with
CVVH and changed to IHD after hemodynamics were stable and
patient mobility increased. Only in 1 patient was RRT initiated
with IHD. Target activated partial thromboplastin time (aPTT)
(Roche Diagnostics, Mannheim, Germany, normal value 20-22
seconds) during RRT was 50 to 80 seconds and 40 to 60 seconds
in periods without CVVD or IHD. Before the start of RRT,
argatroban administration was started with a continuous infusion
of 1 g · kg1 · min1 for 1 hour. Thereafter, the aPTT was
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